A Phase 2/3 interventional study of Lenalidomide and Gemcitabine in Diffuse Large B-cell Lymphoma, sponsored by Celgene. Completed at 57 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-25.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 71 studies testing lenalidomide in Lymphoma, Large B-Cell, Diffuse — 14 open to participants now, 29 under way, 4 of them phase 3. Lenalidomide · Lymphoma, Large B-Cell, Diffuse.
Among the 71 studies testing lenalidomide in Lymphoma, Large B-Cell, Diffuse, this one is the 19th largest by enrollment of the 70 interventional ones that give a count, is one of 5 that started in 2010, is the only one in phase 2/3, and was the 13th registered.
1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
Browse Lymphoma, Large B-Cell, Diffuse studies →14 of the 71 studies testing lenalidomide in Lymphoma, Large B-Cell, Diffuse are open now, in 4 countries. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea · Sites in Spain
Ages 18+
Ruijin Hospital · Sites in China
Ages 18–75
Ruijin Hospital · Sites in China
Ages 70+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
By country, each count listing its studies:
Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 50 · Phase 3 8
First in 2002; this study’s year is marked. 5 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 111 is above the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Median enrollment 55 across the 70 interventional studies. Of the 31 that completed or were terminated, 15 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 71 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
22 studies in Lymphoma, Large B-Cell, Diffuse by Bristol-Myers Squibb: none open now, 1 under way, none of them phase 3. Of 20 finished, 11 (55%) have results posted.
Among the 22 studies in Lymphoma, Large B-Cell, Diffuse by Bristol-Myers Squibb, this one is the 8th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2010, is the only one in phase 2/3, and was the 3rd registered.
Bristol-Myers Squibb’s Lymphoma, Large B-Cell, Diffuse studies by the year they started, since 2007.
4 of the studies testing lenalidomide in Lymphoma, Large B-Cell, Diffuse that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04978584M.D. Anderson Cancer CenterRituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study | 2027-01-16 |
| NCT06015880National Cancer Institute (NCI)Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | 2027-06-30 |
| NCT04609046National Cancer Institute (NCI)Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma | 2027-08-01 |
| NCT03223610National Cancer Institute (NCI)Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma | 2027-08-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 71 studies testing lenalidomide in Lymphoma, Large B-Cell, Diffuse, from their registry updates:
Among Bristol-Myers Squibb’s 22 in Lymphoma, Large B-Cell, Diffuse:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare lenalidomide to a control drug and see which one delays Diffuse Large B-Cell Lymphoma (DLBCL) disease progression longer.
This research study is for patients who have been diagnosed with Diffuse Large B-cell Lymphoma (DLBCL) that did not respond to (refractory) or that has come back after chemotherapy treatment (relapsed). Lymphoma is a cancer of a type of blood cell called lymphocytes. DLBCL is just one type of lymphoma. Within DLBCL there are two different subtypes called Germinal Center B-cell (GCB) and non-GCB which can be determined by cell surface marker tests or by gene expression tests. Scientists can look at cells and genes in the laboratory and see that the two kinds are different, but they don't know yet what the difference means. To patients and doctors these two kinds seem the same. Right now doctors don't usually do tests to find out which kind a patient has because the treatment is the same for both.
This study will have two stages, 1 and 2. The main purpose of Stage 1 is to separate patients by subtype and then test whether patients taking lenalidomide or any one of four other drugs have a better response. It is possible that lenalidomide will work better than one of the other drugs in zero, one, or both subtypes. Stage 2 will further test only the subtype(s) from Stage 1 that showed a good response to lenalidomide. The main purpose of Stage 2 is to test how long patients are disease free on lenalidomide compared to one of the four other drugs.
On 29 January 2013 the enrolment goal for the Stage 1 portion of the study was met and enrollment was stopped. The final analysis for Stage 1 was performed as of the 04 Jul 2013 data cutoff date. According to the Stage 1 results as assessed by the independent response adjudication committee (IRAC), neither subtype met the pre specified requirement to be further studied in Stage 2. Additionally, a suitable assay for the selection of participants for the Stage 2 study was not available. Therefore, on 6 January 2014, Celgene decided to not open Stage 2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lenalidomide 25 mg capsules by mouth on days 1-21 of each 28 day cycle. For patients with Creatinine Clearance ≥ 30 mL/min but \< 60 mL/min, lenalidomide 10 mg (max escalation is 15 mg).
Drug: Lenalidomide
One of the following: Gemcitabine, Oxaliplatin, Rituximab, or Etoposide
Drug: Gemcitabine · Drug: Oxaliplatin · Drug: Rituximab · Drug: Etoposide
Lenalidomide 25 mg orally for 21/28 days until Diffuse Large B-Cell Lymphoma (DLBCL) progressive disease. For patients with Creatinine Clearance ≥ 30 mL/min but \< 60 mL/min, lenalidomide 10 mg (max escalation is 15 mg).
Suggested starting doses and regimens for Gemcitabine is 1,250 mg/m\^2 intravenous (IV) administration on days 1, 8, 15 every 28 days for 6 Cycles or 1,000 mg/m\^2 IV days 1 and 15 every 28 days for 6 Cycles
Suggested starting dose and regimen for Oxaliplatin is 100 mg/m\^2 IV day 1 for 21 days for 6 Cycles
Suggested starting dose for Rituximab is 375 mg/m\^2 IV days 1, 8, 15, 22 during Cycle 1, and if stable disease at Week 12, also on Day 1 of Cycles 4, 6, 8, and 10 (CD20+ patients only)
Suggested starting doses for Etoposide are: 100 mg/m\^2 IV days 1-5 every 28 days for 6 Cycles, or 100 mg/m\^2 IV days 1-3 every 28 days for 6 Cycles, or 50 mg/m\^2 oral days 1-21 every 28 days for 6 Cycles, or 50 mg/m\^2 oral days 1-14 every 28 days for 6 Cycles, or 50 mg/m\^2 oral days 1-10 every 28 days for 6 Cycles
Stage 1: Percentage of Participants With an Overall Response According to the International Working Group (IWG) Response Criteria for Non Hodgkin's Lymphoma (NHL), Cheson 1999 and Evaluated by the Independent Response Adjudication Committee (IRAC)
An overall response is a complete response (CR), unconfirmed complete response (CRu) or partial response (PR) and was evaluated by the IRAC. A CR = complete disappearance of disease and related symptoms. Lymph nodes and nodal masses regressed on computed tomography to normal size (≤ 1.5 cm in their greatest transverse diameter for nodes \> 1.5 cm prior to therapy and ≤ 1.0 cm in their short axis for nodes 1.1-1.5 cm in their long axis and \> 1.0 cm in their short axis prior to therapy). Spleen and/or liver not palpable on exam, normal size by imaging, and absence of nodules related to lymphoma. If bone marrow was involved prior to therapy, infiltrate must have cleared on repeat biopsy. PR = ≥ 50% decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses. No increase in other nodes, liver, or spleen. Splenic and hepatic nodules regressed by ≥ 50% in their SPD or for single nodules, in the greatest transverse diameter;no new disease.
Time frame: From the date of randomization to the data cut-off of 4 July 2013; when all patients reached the scheduled 16-week assessment or had progressed/died before the scheduled 16-week assessment); the median study duration was 27.0 and 19.7 weeks, respectively.
Stage 1: Percentage of Participants With an Overall Response According to the IWG Response Criteria Based on the Investigators Assessment at the Final Data Cut During the Core Treatment Phase
Response was defined as having a CR, CRu or PR, based on IWG 1999 Response Criteria for NHL as evaluated by the investigators. CR = complete disappearance of disease and disease related symptoms. All lymph nodes and nodal masses regressed on computed tomography to normal size (≤ 1.5 cm in their greatest transverse diameter for nodes \> 1.5 cm prior to therapy and ≤ 1.0 cm in their short axis for nodes 1.1-1.5 cm in their long axis and \> 1.0 cm in their short axis prior to therapy). Spleen and/or liver not palpable on physical exam, normal size by imaging, and absence of nodules related to lymphoma. If BM was involved prior to therapy, infiltrate must have cleared on repeat biopsy. PR = ≥ 50% decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses. No increase in the other nodes, liver, or spleen. Splenic and hepatic nodules regressed by ≥ 50% in their SPD or, for single nodules, in the greatest transverse diameter. No new disease.
Time frame: From the date of randomization to the final data cut-off date of 18 May 2018; median study duration was 27.0 and 19.7 weeks, respectively.
Number of Participants With Treatment Emergent Events (TEAEs) in the Overall Treatment Phase by Initial Treatment Assignment
A TEAE was defined as an AE that begins or worsens in intensity of frequency on or after the first dose of study drug through 28 days after last dose of study drug. A serious adverse event (SAE) is any: * Death; * Life-threatening event; * Any inpatient hospitalization or prolongation of existing hospitalization; * Persistent or significant disability or incapacity; * Congenital anomaly or birth defect; * Any other important medical event The investigator determined the relationship of an AE to study drug based on the timing of the AE relative to drug administration and whether or not other drugs, therapeutic interventions, or underlying conditions could provide a sufficient explanation for the event.The severity of an AE was evaluated by the investigator according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (Version 4.03) where Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death
Time frame: From first dose of study drug to the final data cut-off date of 18 May 2018; median study duration was 27.0 and 19.7 weeks, respectively.
Stage 2: Overall Response Rate (ORR)
ORR is defined as: Complete Response + Complete Response unconfirmed + Partial Response based on the International Lymphoma Workshop Response Criteria \[IWRC\] (Cheson 1999).
Time frame: Approximately 3.5 years
Stage 2: Duration of Response (DoR)
Length of time of overall response (Complete Response + Complete Response unconfirmed + Partial Response) based on the International Lymphoma Workshop Response Criteria \[IWRC\] (Cheson 1999).
Time frame: Approximately 3.5 years
Stage 2: Overall Survival (OS)
Overall survival was defined as time from randomization until death of any cause.
Time frame: Approximately 3.5 years
Stage 2: Duration of Complete Response
Length of time of complete response (Complete Response + Complete Response unconfirmed) based on the International Lymphoma Workshop Response Criteria \[IWRC\] (Cheson 1999).
Time frame: Approximately 3.5 years
Stage 2: Overall Response Rate for With a Duration of Response Lasting ≥ 16 Weeks
Complete Response + Complete Response unconfirmed + Partial Response for participants with a duration of response lasting ≥ 16 weeks based on the International Lymphoma Workshop Response Criteria \[IWRC\] (Cheson 1999).
Time frame: Approximately 3.5 years
Stage 2: Time to Progression
Length of time until disease progression occurs
Time frame: Approximately 3.5 years
Stage 2: Health Related Quality of Life Questionnaires
Quality of Life based on the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and the EQ-5D assessments
Time frame: Approximately 3.5 years
Stage 1: Percentage of Participants With a Durable Overall Response (dORR) According to the IWG Response Criteria as Assessed by the Investigators at the Final Data Cut During the Core Treatment Phase
Durable overall response rate was defined as the percentage of participants who maintained a response for at least 16 weeks after initial response.
Time frame: From the date of randomization to the final data cut-off date of 18 May 2018; median study duration was 27.0 and 19.7 weeks, respectively.
Stage 1: Percentage of Participants With a Complete Response According to the IWG Response Criteria as Assessed by the Investigators at the Final Data Cut During the Core Treatment Phase
A complete response was defined as participants with a complete response (CR), or unconfirmed complete response (CRu) based on IWG 1999 Response Criteria for NHL as assessed by the investigator. A CR is a complete disappearance of all disease with the exception of nodes. No new lesions. Previously enlarged organs must have regressed and not be palpable. Bone marrow must be negative if positive at baseline. Normalization of markers. CR Unconfirmed (CRu) does not qualify for CR above, due to a residual nodal mass or an indeterminate BM.
Time frame: From the date of randomization to the final data cut-off date of 18 May 2018; median study duration was 27.0 and 19.7 weeks, respectively.
Stage 1: Kaplan Meier Estimates of Duration of Overall Response (DoR) as Assessed by the Investigators at the Final Data Cut During the Core Treatment Phase
Duration of overall response was calculated as the time of initial response (CR+CRu+PR) until documented disease progression determinted by computerized scan CT scan or MRI or death due to lymphoma, whichever occurred earlier, for participants who responded.
Time frame: From the date of randomization to the final data cut-off date of 18 May 2018; median study duration was 27.0 and 19.7 weeks, respectively.
Stage 1: Kaplan Meier Estimates of Duration of Complete Response (DoCR) as Assessed by the Investigators at the Final Data Cut During the Core Treatment Phase
Duration of complete response was defined as the time from the first documented complete response (CR + CRu) until the first disease progression or death for participants who had a CR.
Time frame: From the date of randomization to the final data cut-off date of 18 May 2018; median study duration was 27.0 and 19.7 weeks, respectively.
Stage 1: Kaplan Meier Estimates of Progression-Free Survival As Assessed By The Investigators At The Final Data Cut During The Core Treatment Phase
Progression-free survival was defined as the time from randomization to the first documented disease progression or death due to any cause.
Time frame: From the date of randomization to the final data cut-off date of 18 May 2018; median study duration was 27.0 and 19.7 weeks, respectively.
Stage 1: Kaplan Meier Estimates of Overall Survival As Assessed by the Investigators at the Final Data Cut During The Core Treatment Phase
Overall survival was defined as time from randomization until death of any cause.
Time frame: From the date of randomization to the final data cut-off date of 18 May 2018; median study duration was 27.0 and 19.7 weeks, respectively.
Stage 2: Progression-Free Survival
Number of participants who survive without progressing based on the International Working Group Response Criteria \[IWG\].
Time frame: Approximately 3.5 years
Screening and enrollment occurred at 43 sites, including 10 in the United States, 9 in France, 7 in the United Kingdom; 4 in Spain, 4 in Italy, 3 each in Austria and Australia, 2 in the Czech Republic, and 1 in Sweden.
| Milestone | Lenalidomide | Investigators Choice (Control Arm) |
|---|---|---|
| Started | 54 | 57 |
| Received ≥ one dose study drug | 54 | 55 |
| Lenalidomide crossover | 0 | 29 |
| Discontinued treatment after ≥ 6 cycles | 14 | 0 |
| Completed | 0 | 4 |
| Not completed | 54 | 53 |
| Withdrew: Adverse event | 6 | 8 |
| Withdrew: Death | 3 | 5 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Disease progression | 40 | 35 |
| Withdrew: Miscellaneous | 4 | 3 |
| Withdrew: Missing | 0 | 1 |
An overall response is a complete response (CR), unconfirmed complete response (CRu) or partial response (PR) and was evaluated by the IRAC. A CR = complete disappearance of disease and related symptoms. Lymph nodes and nodal masses regressed on computed tomography to normal size (≤ 1.5 cm in their greatest transverse diameter for nodes \> 1.5 cm prior to therapy and ≤ 1.0 cm in their short axis for nodes 1.1-1.5 cm in their long axis and \> 1.0 cm in their short axis prior to therapy). Spleen and/or liver not palpable on exam, normal size by imaging, and absence of nodules related to lymphoma. If bone marrow was involved prior to therapy, infiltrate must have cleared on repeat biopsy. PR = ≥ 50% decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses. No increase in other nodes, liver, or spleen. Splenic and hepatic nodules regressed by ≥ 50% in their SPD or for single nodules, in the greatest transverse diameter;no new disease.
| percentage of participants | Lenalidomide | Investigators Choice (IC) |
|---|---|---|
| ORR for All Participants | 27.5 (15.9 to 41.7) | 11.8 (4.4 to 23.9) |
| GCB Subtype | 26.1 (10.2 to 48.4) | 12.0 (2.5 to 31.2) |
| Non-GCB | 28.6 (13.2 to 48.7) | 11.5 (2.4 to 30.2) |
Response was defined as having a CR, CRu or PR, based on IWG 1999 Response Criteria for NHL as evaluated by the investigators. CR = complete disappearance of disease and disease related symptoms. All lymph nodes and nodal masses regressed on computed tomography to normal size (≤ 1.5 cm in their greatest transverse diameter for nodes \> 1.5 cm prior to therapy and ≤ 1.0 cm in their short axis for nodes 1.1-1.5 cm in their long axis and \> 1.0 cm in their short axis prior to therapy). Spleen and/or liver not palpable on physical exam, normal size by imaging, and absence of nodules related to lymphoma. If BM was involved prior to therapy, infiltrate must have cleared on repeat biopsy. PR = ≥ 50% decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses. No increase in the other nodes, liver, or spleen. Splenic and hepatic nodules regressed by ≥ 50% in their SPD or, for single nodules, in the greatest transverse diameter. No new disease.
| Percentage of participants | Lenalidomide | Investigators Choice (IC) |
|---|---|---|
| Stage 1: Percentage of Participants With an Overall Response According to the IWG Response Criteria Based on the Investigators Assessment at the Final Data Cut During the Core Treatment Phase | 29.4 (17.5 to 43.8) | 13.7 (5.7 to 26.3) |
Durable overall response rate was defined as the percentage of participants who maintained a response for at least 16 weeks after initial response.
| percentage of participants | Lenalidomide | Investigators Choice (Control Arm) |
|---|---|---|
| Stage 1: Percentage of Participants With a Durable Overall Response (dORR) According to the IWG Response Criteria as Assessed by the Investigators at the Final Data Cut During the Core Treatment Phase | 23.5 (12.8 to 37.5) | 9.8 (3.3 to 21.4) |
A complete response was defined as participants with a complete response (CR), or unconfirmed complete response (CRu) based on IWG 1999 Response Criteria for NHL as assessed by the investigator. A CR is a complete disappearance of all disease with the exception of nodes. No new lesions. Previously enlarged organs must have regressed and not be palpable. Bone marrow must be negative if positive at baseline. Normalization of markers. CR Unconfirmed (CRu) does not qualify for CR above, due to a residual nodal mass or an indeterminate BM.
| percentage of participants | Lenalidomide | Investigators Choice (IC) |
|---|---|---|
| Stage 1: Percentage of Participants With a Complete Response According to the IWG Response Criteria as Assessed by the Investigators at the Final Data Cut During the Core Treatment Phase | 13.7 (5.7 to 26.3) | 3.9 (0.5 to 13.5) |
Duration of overall response was calculated as the time of initial response (CR+CRu+PR) until documented disease progression determinted by computerized scan CT scan or MRI or death due to lymphoma, whichever occurred earlier, for participants who responded.
| Weeks | Lenalidomide | Investigators Choice (Control Arm) |
|---|---|---|
| Stage 1: Kaplan Meier Estimates of Duration of Overall Response (DoR) as Assessed by the Investigators at the Final Data Cut During the Core Treatment Phase | 64.7 (29.1 to 141.6) | 63.1 (15.3 to 79.4) |
Duration of complete response was defined as the time from the first documented complete response (CR + CRu) until the first disease progression or death for participants who had a CR.
| Weeks | Lenalidomide | Investigators Choice (Control Arm) |
|---|---|---|
| Stage 1: Kaplan Meier Estimates of Duration of Complete Response (DoCR) as Assessed by the Investigators at the Final Data Cut During the Core Treatment Phase | 66.4 (22.1 to NA) | 179.3 (63.1 to 295.4) |
Progression-free survival was defined as the time from randomization to the first documented disease progression or death due to any cause.
| Weeks | Lenalidomide | Investigators Choice (IC) |
|---|---|---|
| Stage 1: Kaplan Meier Estimates of Progression-Free Survival As Assessed By The Investigators At The Final Data Cut During The Core Treatment Phase | 9.6 (7.6 to 17.1) | 7.1 (6.0 to 8.3) |
Overall survival was defined as time from randomization until death of any cause.
| Weeks | Lenalidomide | Investigators Choice (IC) |
|---|---|---|
| Stage 1: Kaplan Meier Estimates of Overall Survival As Assessed by the Investigators at the Final Data Cut During The Core Treatment Phase | 31.0 (16.6 to 43.7) | 24.6 (12.7 to 34.9) |
A TEAE was defined as an AE that begins or worsens in intensity of frequency on or after the first dose of study drug through 28 days after last dose of study drug. A serious adverse event (SAE) is any: * Death; * Life-threatening event; * Any inpatient hospitalization or prolongation of existing hospitalization; * Persistent or significant disability or incapacity; * Congenital anomaly or birth defect; * Any other important medical event The investigator determined the relationship of an AE to study drug based on the timing of the AE relative to drug administration and whether or not other drugs, therapeutic interventions, or underlying conditions could provide a sufficient explanation for the event.The severity of an AE was evaluated by the investigator according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (Version 4.03) where Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death
| Participants | Lenalidomide | Investigators Choice (IC) |
|---|---|---|
| Any TEAEs | 54 | 55 |
| Any Treatment Related TEAE | 49 | 45 |
| Any TEAE Grade ≥ 3 | 43 | 53 |
| Any TEAE Grade ≥ 4 | 29 | 36 |
| Any TEAE Grade 5 | 9 | 18 |
| Any TEAE Grade 3 or 4 | 42 | 52 |
| Any Treatment Related TEAE Grade ≥ 3 | 30 | 39 |
| Any Treatment Related TEAEs Grade ≥ 4 | 15 | 21 |
| Any Treatment Related TEAE Grade 5 | 0 | 2 |
| Any Treatment Related TEAE Grade 3 or 4 | 30 | 39 |
| Any Serious Adverse Events (SAEs) | 31 | 42 |
| Any Treated Related SAEs | 14 | 21 |
| Any AE leading to stopping of study drug | 11 | 17 |
| Any drug related AE leading to halt of study drug | 5 | 4 |
| Any AE leading to dose interruption/reduct | 32 | 34 |
| Any drug related AE leading to interruption/reduct | 27 | 30 |
ORR is defined as: Complete Response + Complete Response unconfirmed + Partial Response based on the International Lymphoma Workshop Response Criteria \[IWRC\] (Cheson 1999).
No measurements were reported for this outcome.
Length of time of overall response (Complete Response + Complete Response unconfirmed + Partial Response) based on the International Lymphoma Workshop Response Criteria \[IWRC\] (Cheson 1999).
No measurements were reported for this outcome.
Overall survival was defined as time from randomization until death of any cause.
No measurements were reported for this outcome.
Number of participants who survive without progressing based on the International Working Group Response Criteria \[IWG\].
No measurements were reported for this outcome.
Length of time of complete response (Complete Response + Complete Response unconfirmed) based on the International Lymphoma Workshop Response Criteria \[IWRC\] (Cheson 1999).
No measurements were reported for this outcome.
Complete Response + Complete Response unconfirmed + Partial Response for participants with a duration of response lasting ≥ 16 weeks based on the International Lymphoma Workshop Response Criteria \[IWRC\] (Cheson 1999).
No measurements were reported for this outcome.
Length of time until disease progression occurs
No measurements were reported for this outcome.
Quality of Life based on the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and the EQ-5D assessments
No measurements were reported for this outcome.
Collected over From first dose of study drug to the final data cut-off date of 18 May 2018; the median study duration of 27.0 and 19.7 weeks, respectively.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lenalidomide | 48/54 (88.9%) | 31/54 (57.4%) | 53/54 (98.1%) |
| Investigator's Choice | 51/55 (92.7%) | 42/55 (76.4%) | 52/55 (94.5%) |
| Event | Lenalidomide | Investigator's Choice |
|---|---|---|
| DIFFUSE LARGE B-CELL LYMPHOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 4/54 | 10/55 |
| ANAEMIABlood and lymphatic system disorders | 4/54 | 3/55 |
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 4/54 | 2/55 |
| CELLULITISInfections and infestations | 0/54 | 4/55 |
| PNEUMONIAInfections and infestations | 3/54 | 3/55 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 1/54 | 3/55 |
| VOMITINGGastrointestinal disorders | 0/54 | 3/55 |
| HYPERCALCAEMIAMetabolism and nutrition disorders | 1/54 | 3/55 |
| PYREXIAGeneral disorders | 2/54 | 2/55 |
| URINARY TRACT INFECTIONInfections and infestations | 2/54 | 0/55 |
| Event | Lenalidomide | Investigator's Choice |
|---|---|---|
| ANAEMIABlood and lymphatic system disorders | 17/54 | 31/55 |
| NEUTROPENIABlood and lymphatic system disorders | 23/54 | 18/55 |
| NAUSEAGastrointestinal disorders | 10/54 | 23/55 |
| FATIGUEGeneral disorders | 19/54 | 16/55 |
| DIARRHOEAGastrointestinal disorders | 18/54 | 16/55 |
| PYREXIAGeneral disorders | 16/54 | 18/55 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 13/54 | 17/55 |
| CONSTIPATIONGastrointestinal disorders | 16/54 | 16/55 |
| DECREASED APPETITEMetabolism and nutrition disorders | 8/54 | 15/55 |
| COUGHRespiratory, thoracic and mediastinal disorders | 13/54 | 10/55 |
Modified Intent to Treat (mITT) = all study participants randomized with a diffuse large B-cell lymphoma (DLBCL) diagnosis and germinal center B-cell (GCB)/non-germinal center B (non-GCB) subtype confirmed by central pathology, and who received at least one dose of study drug (lenalidomide or Investigator's choice). Nine participants were excluded.
| Age, Continuous(years) | Lenalidomide | Investigators Choice (IC) | Total |
|---|---|---|---|
| Mean | 64.7 ± 13.43 | 62.8 ± 13.94 | 63.75 ± 13.69 |
| Sex: Female, Male(Participants) | Lenalidomide | Investigators Choice (IC) | Total |
|---|---|---|---|
| Female | 21 | 20 | 41 |
| Male | 30 | 31 | 61 |
| Race/Ethnicity, Customized(Participants) | Lenalidomide | Investigators Choice (IC) | Total |
|---|---|---|---|
| Asian | 1 | 1 | 2 |
| Black/African American | 0 | 1 | 1 |
| White | 38 | 36 | 74 |
| Missing | 9 | 11 | 20 |
| Other (Unspecified) | 3 | 2 | 5 |
| Eastern Cooperative Oncology Performance Status (ECOG)](Participants) | Lenalidomide | Investigators Choice (IC) | Total |
|---|---|---|---|
| 0 = (Fully Active) | 18 | 15 | 33 |
| 1 (Restrictive but Ambulatory) | 24 | 28 | 52 |
| 2 (Ambulatory but Unable to Work) | 7 | 8 | 15 |
| 3 (Limited Self-Care) | 0 | 0 | 0 |
| 4 (Completely Disabled) | 1 | 0 | 1 |
| Missing | 1 | 0 | 1 |
| Creatinine Clearance (CrCl)(Participants) | Lenalidomide | Investigators Choice (IC) | Total |
|---|---|---|---|
| ≥ 60 mL/min | 32 | 43 | 75 |
| ≥ 30 but < 60 mL/min | 18 | 7 | 25 |
| Missing | 1 | 1 | 2 |
| Disease Stage of DLBCL at Enrollment(Participants) | Lenalidomide | Investigators Choice (IC) | Total |
|---|---|---|---|
| IA | 1 | 3 | 4 |
| IB | 1 | 0 | 1 |
| IIA | 8 | 7 | 15 |
| IIB | 3 | 1 | 4 |
| IIIA | 13 | 13 | 26 |
| IIIB | 2 | 4 | 6 |
| IVA | 17 | 14 | 31 |
| IVB | 6 | 9 | 15 |
| Diffuse Large B-Cell Lymphoma (DLBCL) Subtypes - Germinal Center B-Cell (GCB) and non-GCB(Participants) | Lenalidomide | Investigators Choice (IC) | Total |
|---|---|---|---|
| Germinal Center B-Cell Type | 23 | 25 | 48 |
| Non-Germinal Center B-Cell Type | 28 | 26 | 54 |
Ran from Sep 2010 to primary completion in Jul 2013, 34 months.
Results were first posted in Aug 2014, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lenalidomide
Lymphoma, Large B-Cell, Diffuse →